Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (4) , 722-729
- https://doi.org/10.1111/j.1538-7836.2010.03746.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trialsJournal of Thrombosis and Haemostasis, 2009
- Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by AvidinBlood, 2008
- Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapyJournal of Thrombosis and Haemostasis, 2008
- Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trialThe Lancet, 2008
- Extended Prophylaxis of Venous Thromboembolism with IdraparinuxNew England Journal of Medicine, 2007
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluationJournal of Thrombosis and Haemostasis, 2004
- Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic PentasaccharideBlood, 1998
- Pretargeting strategies for radio-immunoguided tumour localisation and therapyEuropean Journal Of Cancer, 1997
- Pharmacokinetics of [3H]Biotin Bound to Different Avidin AnaloguesJournal of Drug Targeting, 1995